Vinorelbine and Gemcitabine as Second- Or Third-Line Therapy for Malignant Pleural Mesothelioma

Lung Cancer - Netherlands
doi 10.1016/j.lungcan.2014.03.006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- Or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2009English

Malignant Pleural Mesothelioma Presenting as Achalasia.

Internal Medicine
Internal MedicineMedicine
1994English

Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma

Annals of Thoracic Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2012English

Malignant Pleural Mesothelioma

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2009English

Malignant Pleural Mesothelioma: Management and Role of Radiation Therapy

Journal of Nuclear Medicine & Radiation Therapy
2013English

Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2014English

Emerging Therapies for Malignant Pleural Mesothelioma

Current Respiratory Care Reports
2012English

MicroRNAs as Potential Biomarkers in Malignant Pleural Mesothelioma

Current Biomarker Findings
BiochemistryClinical Biochemistry
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy